Adherence-adjusted estimates of benefits and harms from treatment with amoxicillin for LRTI: secondary analysis of a 12-country randomised placebo-controlled trial using randomisation-based efficacy estimators

David Gillespie(Cardiff University), Paul Little(University of Antwerp), Mark Mullee(University of Southampton), Theo Verheij(Utrecht University), Daniel Farewell(Cardiff University), Christopher Butler(University of Oxford), Kerenza Hood(NHS Digital), Beth Stuart(Queen Mary University of London), Herman Goossens(University of Antwerp)
BMJ Open
March 1, 2015
Cited by 16


Related Papers